High-risk human papillomavirus infection
Conditions
Interventions
Experimental Group:Participants in the experimental group will receive Anti-HPV gel dressing treatment, starting on the first day after the end of menstruation. The gel will be administered intravagin
Control group:Participants in the control group will not receive any intervention treatment related to HPV infection.
Sponsors
Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1 Females aged =18 years with a history of sexual activity; 2 High-risk HPV infection confirmed by cervical HPV testing; 3 Normal cognitive and communication abilities, willingness to use effective contraception during the study, and abstinence from sexual intercourse during the treatment period; 4 Capable of complying with all study procedures and providing signed informed consent.
Exclusion criteria
Exclusion criteria: 1 Patients with HPV16 or HPV18 positivity and high-grade squamous intraepithelial lesion or worse (HSIL+); 2 Patients with other high-risk HPV subtypes (excluding HPV16/18) requiring further colposcopy; 3 Patients with cervical cancer; 4 Pregnant or lactating women; 5 Individuals with a history of allergies or known hypersensitivity to any component of the investigational gel dressing (e.g., carbomer); 6 Malignancy or other diseases that may compromise immune function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative conversion rate;Total effective rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vaginal microecosystem; | — |
Countries
China
Contacts
Public ContactLyu Tao
Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital
Outcome results
None listed